Discover how the Phase III MATTERHORN trial is redefining outcomes for patients with early-stage gastric and gastroesophageal cancers through the first perioperative immunotherapy regimen to show a survival advantage.
Nancy Ghattas
Advertisement
VP, US Oncology Commercial Franchise Head of Immuno-Oncology, AstraZeneca
Articles by Nancy Ghattas
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Thermo Fisher, Lundbeck Announce New OpenAI Partnerships Advancing AI in Drug Development
2
Using Global Patient Data to Design Smarter, More Inclusive Clinical Trials
3
ACT Brief: AI Partnerships, Data-Driven Site Activation, and FDA Approval for Omvoh’s Single-Injection Regimen
4
Imfinzi Regimen Demonstrates 22% Survival Benefit in Early Gastric and GEJ Cancer
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
